Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Capital Expenditures (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Capital Expenditures for 3 consecutive years, with $10000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures fell 99.58% to $10000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $31000.0 through Dec 2025, down 98.81% year-over-year, with the annual reading at $31000.0 for FY2025, 98.81% down from the prior year.
  • Capital Expenditures for Q3 2025 was $10000.0 at Inhibrx Biosciences, down from $21000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $3.4 million in Q4 2023, with the low at -$100000.0 in Q2 2024.
  • Average Capital Expenditures over 3 years is $860125.0, with a median of $164000.0 recorded in 2024.
  • The sharpest move saw Capital Expenditures skyrocketed 192.73% in 2024, then tumbled 99.58% in 2025.
  • Over 3 years, Capital Expenditures stood at $3.4 million in 2023, then plummeted by 99.54% to $16000.0 in 2024, then crashed by 37.5% to $10000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $10000.0, $21000.0, and $16000.0 for Q3 2025, Q2 2025, and Q4 2024 respectively.